

Factor VIII requirement to maintain a target plasma level in severe hemophilia A: influences of variance in pharmacokinetics

Journal of Thrombosis and Haemostasis

8, 269-275

DOI: [10.1111/j.1538-7836.2009.03703.x](https://doi.org/10.1111/j.1538-7836.2009.03703.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prophylaxis in the haemophilia population. <i>Haemophilia</i> , 2010, 16, 181-188.	1.0	62
2	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. <i>The Cochrane Library</i> , 2011, , CD003429.	1.5	92
3	Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. <i>Blood</i> , 2011, 118, 3698-3707.	0.6	25
4	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. <i>Haemophilia</i> , 2011, 17, 2-10.	1.0	170
5	A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. <i>Haemophilia</i> , 2011, 17, 179-184.	1.0	31
6	FVIII administration in surgery. <i>Haemophilia</i> , 2011, 17, 828-829.	1.0	1
7	Joint protection in haemophilia. <i>Haemophilia</i> , 2011, 17, 1-23.	1.0	107
8	Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1784-1790.	1.9	30
9	The factor VIII inhibitor assays can be standardized: results of a workshop. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2003-2008.	1.9	19
10	Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial. <i>Expert Review of Hematology</i> , 2011, 4, 495-507.	1.0	7
11	Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 79-94.	1.5	74
12	The Diagnosis and Management of Congenital Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 727-734.	1.5	75
13	Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. <i>American Journal of Therapeutics</i> , 2012, , 1.	0.5	2
14	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. <i>Blood</i> , 2012, 119, 612-618.	0.6	181
15	Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1581-1590.	1.9	54
16	A Canadian survey of self-infusion practices in persons with haemophilia A. <i>Haemophilia</i> , 2012, 18, e403-5.	1.0	2
17	Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®). <i>Drugs</i> , 2012, 72, 987-1007.	4.9	12
18	34 Faktorenkonzentrate. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 969-977.	0.8	31
20	Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients. <i>Haemophilia</i> , 2012, 18, 187-192.	1.0	6
21	A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8) Tj ETQq0 0.0 rgBT /Overlock 10	1.0	40
22	Personalized prophylaxis. <i>Haemophilia</i> , 2012, 18, 131-135.	1.0	80
23	Tertiary prophylaxis in adults: is there a rationale?. <i>Haemophilia</i> , 2012, 18, 722-728.	1.0	26
24	Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. <i>Haemophilia</i> , 2012, 18, 855-859.	1.0	44
25	A randomized comparison of two prophylaxis regimens and a paired comparison of onâ€demand and prophylaxis treatments in hemophilia A management. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 359-367.	1.9	241
26	The hope and reality of longâ€acting hemophilia products. <i>American Journal of Hematology</i> , 2012, 87, S33-9.	2.0	45
27	Treatment for life for severe haemophilia Aâ€ A costâ€utility model for prophylaxis vs. onâ€demand treatment. <i>Haemophilia</i> , 2013, 19, e228-38.	1.0	48
28	Importance of pharmacokinetics in the management of hemophilia. <i>Pediatric Blood and Cancer</i> , 2013, 60, S27-9.	0.8	26
29	Inherited Abnormalities of Coagulation. <i>Pediatric Clinics of North America</i> , 2013, 60, 1419-1441.	0.9	34
30	Will gene therapy trump factor treatment in hemophilia?. <i>Expert Review of Hematology</i> , 2013, 6, 43-48.	1.0	1
31	Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 711-722.	1.5	11
32	Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 723-731.	1.5	53
33	Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?. <i>Haemophilia</i> , 2013, 19, 882-886.	1.0	19
34	Monitoring <scp>rFVIII</scp> prophylaxis dosing using global haemostasis assays. <i>Haemophilia</i> , 2013, 19, 409-414.	1.0	31
35	Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study. <i>Haemophilia</i> , 2013, 19, 805-807.	1.0	10
36	Long-lasting recombinant factor VIII proteins for hemophilia A. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 37-43.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Managing Hemophilia in Children and Adolescents. , 2013, , 59-78.		2
39	Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. <i>Biologics: Targets and Therapy</i> , 2014, 8, 115.	3.0	20
40	Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. <i>Drug Design, Development and Therapy</i> , 2014, 8, 365.	2.0	11
41	Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. <i>Patient Preference and Adherence</i> , 2014, 8, 1713.	0.8	17
42	Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 687-702.	0.3	26
45	Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity. <i>Haemophilia</i> , 2014, 20, 92-98.	1.0	9
46	Considerations in individualizing prophylaxis in patients with haemophilia A. <i>Haemophilia</i> , 2014, 20, 607-615.	1.0	55
47	Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2014, 20, e100-e101.	1.0	6
48	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the <sc>VERITAS</sc>-Pro scale. <i>Haemophilia</i> , 2014, 20, 616-623.	1.0	32
49	Methods for individualising factor <sc>VIII</sc> dosing in prophylaxis. <i>European Journal of Haematology</i> , 2014, 93, 16-20.	1.1	31
50	The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 39.	1.2	32
51	BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B. <i>Expert Review of Hematology</i> , 2014, 7, 333-342.	1.0	7
52	Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?. <i>Haemophilia</i> , 2014, 20, e406-e408.	1.0	6
54	Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling. <i>Haemophilia</i> , 2015, 21, 300-306.	1.0	24
55	Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. <i>Blood</i> , 2015, 125, 2038-2044.	0.6	286
56	Half-life extension technologies for haemostatic agents. <i>Thrombosis and Haemostasis</i> , 2015, 113, 165-176.	1.8	29
58	The current status of prophylactic replacement therapy in children and adults with haemophilia. <i>British Journal of Haematology</i> , 2015, 169, 777-786.	1.2	52
59	Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics. <i>Journal of Blood Medicine</i> , 2015, 6, 185.	0.7	6

#	ARTICLE	IF	CITATIONS
60	Soy Phosphatidylinositol Containing Nanoparticle Prolongs Hemostatic Activity of B-Domain Deleted Factor VIII in Hemophilia A Mice. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 388-395.	1.6	13
61	Parameters influencing <scp>FVIII</scp> pharmacokinetics in patients with severe and moderate haemophilia A. <i>Haemophilia</i> , 2015, 21, 343-350.	1.0	55
62	Individualizing prophylaxis in hemophilia: a review. <i>Expert Review of Hematology</i> , 2015, 8, 237-246.	1.0	58
63	Switching to recombinant factor <scp>IX</scp> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <scp>IX</scp> consumption and lower bleeding rates. <i>British Journal of Haematology</i> , 2015, 168, 113-123.	1.2	31
64	Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: A non-interventional study in emerging countries. <i>Haemophilia</i> , 2015, 21, e167-e175.	1.0	7
65	Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? <i>Haemophilia</i> Sept 2014;20(5):601-3. <i>Haemophilia</i> , 2015, 21, e235-6.	1.0	3
66	Individualizing Factor Replacement Therapy in Severe Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 864-871.	1.5	20
67	Challenges in hemophilia care in Australia and New Zealand. <i>Current Medical Research and Opinion</i> , 2015, 31, 1985-1991.	0.9	6
68	Management of Inherited, Acquired, and Iatrogenically Induced Coagulopathies in Oral Surgery. , 0, , .		0
69	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. <i>Thrombosis and Haemostasis</i> , 2016, 115, 913-920.	1.8	27
70	Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. <i>Haemophilia</i> , 2016, 22, e1-e10.	1.0	26
71	Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 563-576.	1.5	14
72	Effects of moderate-intensity physical exercise on pharmacokinetics of factor <scp>VIII</scp> and von Willebrand factor in young adults with severe haemophilia A: a pilot study. <i>Haemophilia</i> , 2016, 22, e177-83.	1.0	10
73	An innovative outcome-based care and procurement model of hemophilia management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 337-345.	0.7	15
74	Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia?. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 533-540.	1.5	6
75	Dosing regimens, <scp>FVIII</scp> levels and estimated haemostatic protection with special focus on <scp>rFVIIIF</scp>c. <i>Haemophilia</i> , 2016, 22, 389-396.	1.0	33
76	The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1313-1321.	1.5	44
77	Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2141-2147.	1.9	3

#	ARTICLE	IF	CITATIONS
78	Personalized prophylaxis in people with hemophilia A: challenges and achievements. <i>Expert Review of Hematology</i> , 2016, 9, 1203-1208.	1.0	17
79	Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1359-1365.	1.5	7
80	Aspects of prophylactic treatment of hemophilia. <i>Thrombosis Journal</i> , 2016, 14, 30.	0.9	28
82	Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. <i>American Journal of Therapeutics</i> , 2016, 23, e1043-e1056.	0.5	16
83	Association of peak factor <sc>VIII</sc> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. <i>Haemophilia</i> , 2016, 22, 514-520.	1.0	58
84	Global assays in hemophilia. <i>Seminars in Hematology</i> , 2016, 53, 40-45.	1.8	26
85	Factor VIII/factor IX prophylaxis for severe hemophilia. <i>Seminars in Hematology</i> , 2016, 53, 3-9.	1.8	19
86	What is the role for population pharmacokinetics in hemophilia?. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 125-136.	0.5	7
87	Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 977-988.	2.3	20
88	Predicting dose sparing benefit and bleeding risk of pharmacokineticâ€based personalized prophylactic dosing of factor <sc>VIII</sc> products. <i>Haemophilia</i> , 2017, 23, 705-711.	1.0	14
89	Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. <i>Haemophilia</i> , 2017, 23, e170-e179.	1.0	60
90	Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1045-1055.	1.6	31
91	The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. <i>Expert Review of Hematology</i> , 2017, 10, 995-1004.	1.0	24
93	Simoctocog alfa for the treatment of hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1573-1580.	1.4	3
94	Patient powered prophylaxis: A 12â€month study of individualized prophylaxis in adults with severe haemophilia A. <i>Haemophilia</i> , 2017, 23, 877-883.	1.0	14
95	Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 425-430.	0.5	21
96	Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 540-550.	0.5	4
97	The History of Clotting Factor Concentrates Pharmacokinetics. <i>Journal of Clinical Medicine</i> , 2017, 6, 35.	1.0	11

#	ARTICLE	IF	CITATIONS
98	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. <i>Pharmaceutics</i> , 2017, 9, 47.	2.0	17
100	Real life experiences of a PK dosing study – Challenges and lessons learned.. <i>Haemophilia</i> , 2018, 24, e145-e148.	1.0	2
101	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. <i>Blood Reviews</i> , 2018, 32, 265-271.	2.8	41
102	Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. <i>Haemophilia</i> , 2018, 24, e84-e92.	1.0	21
103	Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 143-151.	1.5	3
104	Individualized PK-based prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2018, 24, 3-17.	1.0	28
105	Haemophilia B: Where are we now and what does the future hold?. <i>Blood Reviews</i> , 2018, 32, 52-60.	2.8	41
106	Breakthrough bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2018, 24, 120-125.	1.0	3
107	Gene therapy in hemophilia A: a cost-effectiveness analysis. <i>Blood Advances</i> , 2018, 2, 1792-1798.	2.5	56
108	BAY 949027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies. <i>Haemophilia</i> , 2018, 24, 733-740.	1.0	33
109	Optimizing bleed prevention throughout the lifespan: Womb to Tomb. <i>Haemophilia</i> , 2018, 24, 76-86.	1.0	4
110	Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa) Tj ETQq1 1 0.784314 rgBT /Over Pharmaceuticals, 2018, 11, 75.	1.7	20
111	Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 149-162.	1.1	11
112	Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. <i>Blood Reviews</i> , 2019, 33, 106-116.	2.8	12
113	Investigation of diffusion, practical use, and utility of a medical device for Japanese hemophilia patients in a single institution. <i>Personalized Medicine Universe</i> , 2019, 8, 32-37.	0.1	2
114	Joint Bleeding Tendencies in Adult Patients With Hemophilia: It's Not All Pharmacokinetics. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986205.	0.7	12
115	Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. <i>Blood</i> , 2019, 134, 880-891.	0.6	35
116	Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1288-1296.	1.9	15

#	ARTICLE	IF	CITATIONS
117	Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. <i>Haemophilia</i> , 2019, 25, 408-415.	1.0	10
118	PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital. <i>Pediatric Investigation</i> , 2019, 3, 45-49.	0.6	7
119	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , 2019, 3, 3241-3247.	2.5	85
120	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 192-212.	1.0	10
121	Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. <i>International Journal of Hematology</i> , 2020, 111, 42-50.	0.7	40
122	Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine. <i>Blood Reviews</i> , 2020, 39, 100618.	2.8	24
123	Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1395-1406.	1.8	13
124	Comparison of different prophylactic regimens for Thai children with moderate and severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e211-e213.	1.0	1
125	A non-viral genome editing platform for site-specific insertion of large transgenes. <i>Stem Cell Research and Therapy</i> , 2020, 11, 380.	2.4	9
126	Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. <i>Annals of Hematology</i> , 2020, 99, 2689-2698.	0.8	17
127	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 728-736.	1.8	19
128	Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. <i>Haemophilia</i> , 2020, 26, 575-583.	1.0	29
129	Hematuria in aging men with hemophilia: Association with factor prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 309-317.	1.0	7
130	Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 326-333.	1.0	13
131	Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise. <i>Haemophilia</i> , 2020, 26, 711-717.	1.0	19
132	Redefining prophylaxis in the modern era. <i>Haemophilia</i> , 2021, 27, 21-27.	1.0	8
133	Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. <i>Blood</i> , 2021, 137, 1818-1827.	0.6	43
134	Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinese paediatric patients with haemophilia A: A single-centre study. <i>Haemophilia</i> , 2021, 27, e287-e290.	1.0	2



#	ARTICLE	IF	CITATIONS
135	Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 654-663.	1.9	11
136	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1326-1336.	1.8	12
137	Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 259-265.	0.5	2
138	Review Article- Insights on Hemophilia. <i>International Journal of Pharmaceutical Sciences Review and Research</i> , 2021, 67, 53-62.	0.1	0
139	Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. <i>Pediatric Investigation</i> , 2021, 5, 38-45.	0.6	7
140	Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. <i>Haemophilia</i> , 2021, 27, 626-633.	1.0	1
141	Perspective "The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. <i>Blood Reviews</i> , 2021, 50, 100849.	2.8	4
142	RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 658-668.	2.3	4
143	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1896-1906.	1.9	12
144	An anesthetic management of head and neck cancer reconstructive surgery in a patient having hemophilia A: a case report. <i>Journal of Dental Anesthesia and Pain Medicine</i> , 2021, 21, 261.	0.4	0
145	Individualized approach to prophylactic treatment in patients with severe hemophilia A. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2018, 5, 88-94.	0.1	2
146	Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). <i>JMIR Research Protocols</i> , 2016, 5, e232.	0.5	43
147	Clinical use of factor VIII and factor IX concentrates. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s55-63.	0.3	16
148	2013 revised edition : hemostatic treatment guidelines for hemophilia patients without inhibitors. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2013, 24, 619-639.	0.1	11
149	Transperitoneal hernioplasty in a patient with severe hemophilia A on preventive treatment with emicizumab. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 116-124.	0.1	1
150	Congenital Coagulation Disorders. , 2016, , 93-114.		0
151	Application of Advate® for the treatment of patients with hemophilia A. <i>Bulletin Physiology and Pathology of Respiration</i> , 2020, 1, 77-86.	0.0	0
152	Modern approaches in hemophilia therapy. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2020, 19, 131-138.	0.1	1

#	ARTICLE	IF	CITATIONS
153	Target of prophylaxis in severe haemophilia: more than factor levels. <i>Blood Transfusion</i> , 2013, 11, 327-9.	0.3	11
154	Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 733.	1.0	3
155	Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973. <i>Haemophilia</i> , 2022, 28, 223-229.	1.0	2
156	Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 665-673.	1.0	0
157	How do we optimally utilize factor concentrates in persons with hemophilia?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 206-214.	0.9	4
159	Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience. <i>Haemophilia</i> , 2022, , .	1.0	1
160	Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973). <i>Journal of Clinical Medicine</i> , 2022, 11, 3434.	1.0	1
161	Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia in China. <i>Advances in Therapy</i> , 2022, 39, 3777-3788.	1.3	4
162	Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States. <i>Journal of Blood Medicine</i> , 0, Volume 13, 517-524.	0.7	0
163	The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHES II Study. <i>Journal of Blood Medicine</i> , 0, Volume 13, 505-516.	0.7	6
164	Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	0
165	Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience. <i>The Journal of Haemophilia Practice</i> , 2021, 8, 80-85.	0.2	0
166	Past, Present, and Future Options in the Treatment of Hemophilia A. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2019, 32, ascls.2018001032.	0.1	0
167	Hemophilia in the practice of a general practitioner and hematologist. <i>SpravoĀnik VraĀe ObĀej Praktiki</i> , 2022, , 7-16.	0.0	0
168	Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors. <i>Haemophilia</i> , 2023, 29, 479-487.	1.0	0
169	Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1123-1134.	1.9	3
170	Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab. <i>Expert Review of Hematology</i> , 0, , 1-7.	1.0	0
171	Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 239-252.	0.4	0

#	ARTICLE	IF	CITATIONS
172	The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWFâ€™FVIII clearance in thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2023, 21, 2007-2019.	1.9	1